Recombinant activated factor VII for coagulopathy in fulminant hepatic failure compared with conventional therapy

@article{Shami2003RecombinantAF,
  title={Recombinant activated factor VII for coagulopathy in fulminant hepatic failure compared with conventional therapy},
  author={V. Shami and S. Caldwell and E. E. Hespenheide and K. Arseneau and S. Bickston and B. Macik},
  journal={Liver Transplantation},
  year={2003},
  volume={9}
}
  • V. Shami, S. Caldwell, +3 authors B. Macik
  • Published 2003
  • Medicine
  • Liver Transplantation
    • Severe coagulopathy in fulminant hepatic failure (FHF) is difficult to correct by conventional means. Recombinant activated factor VII (rFVIIa) is an antihemophilic factor that has shown promise in treating coagulopathy in liver disease. Our aim is to review our experience with rFVIIa in treating the coagulopathy of FHF and compare these results with those of conventional therapy. Fifteen patients with FHF who met King's College criteria for orthotopic liver transplantation were studied. All… CONTINUE READING
    View on Wiley
    aasldpubs.onlinelibrary.wiley.com
    213 Citations
    Highly Influencial Citations
    8
    Background Citations
    45
    Methods Citations
    12
    Results Citations
    1
    213 Citations
    Citation Type

    Citation Type

    Use of recombinant factor VIIa in pediatric patients with liver failure and severe coagulopathy.
    • 19
    FVIIa corrects the coagulopathy of fulminant hepatic failure but may be associated with thrombosis: A report of four cases
    • 94
    • PDF
    Recombinant factor VIIa: unregulated continuous use in patients with bleeding and coagulopathy does not alter mortality and outcome.
    • 19
    The use of recombinant factor VIIa in liver diseases
    • 22
    Clinical Usefulness of Recombinant Activated Factor VII in Patients with Liver Failure Undergoing Invasive Procedures
    • 24
    Recombinant factor VIIa: life-saving therapy in a patient with massive bleeding and hepatic failure
    The Use of Activated Recombinant Factor VII in a Patient with Fulminant Hepatic Failure Requiring Placement of an Intracranial Pressure Monitor
    • 7
    Recombinant activated factor VII in liver patients: a retrospective cohort study from Australia and New Zealand
    • 9
    Activated recombinant factor VII in orthotopic liver transplantation.
    • 33
    Recombinant FVIIa in children with liver disease.
    • 17

    References

    SHOWING 1-10 OF 27 REFERENCES
    Safety and efficacy of recombinant factor VIIa in patients with liver disease undergoing laparoscopic liver biopsy.
    • 165
    The treatment of bleeding in hemophilic patients with inhibitors with recombinant factor VIIa.
    • 34
    REDUCED TRANSFUSION REQUIREMENTS BY RECOMBINANT FACTOR VIIa IN ORTHOTOPIC LIVER TRANSPLANTATION: A Pilot Study
    • 251
    • PDF
    Coagulopathy of liver disease
    • 39
    Controlled trial of antithrombin III supplementation in fulminant hepatic failure.
    • 30
    Recombinant factor VIIa corrects prothrombin time in cirrhotic patients: a preliminary study.
    • 262
    Recombinant factor VIIa improves clot formation but not fibrolytic potential in patients with cirrhosis and during liver transplantation
    • 73
    Recombinant activated factor VII as a universal haemostatic agent.
    • U. Hedner
    • Medicine
    • Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis
    • 1998
    • 122
    Clinical experience with recombinant factor VIIa.
    • 211
    Safety and initial clinical efficacy of three dose levels of recombinant activated factor VII (rFVIIa): results of a Phase I study
    • B. Macik, C. Lindley, +7 authors H. Roberts
    • Medicine
    • Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis
    • 1993
    • 65